InMed Pharmaceuticals (FRA:MWG0) Total Liabilities : €2.07 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Total Liabilities?

InMed Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €2.07 Mil.

InMed Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2023 (€1.26 Mil) to Dec. 2023 (€2.28 Mil) but then declined from Dec. 2023 (€2.28 Mil) to Mar. 2024 (€2.07 Mil).

InMed Pharmaceuticals's annual Total Liabilities increased from Jun. 2021 (€2.00 Mil) to Jun. 2022 (€3.51 Mil) but then declined from Jun. 2022 (€3.51 Mil) to Jun. 2023 (€1.86 Mil).

InMed Pharmaceuticals Total Liabilities Historical Data

The historical data trend for InMed Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Total Liabilities Chart

InMed Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

1.05

1.71

2.00

3.51

1.86

InMed Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															2.19	1.86	1.26	2.28	2.07

InMed Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

InMed Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.847	+	(0.015	+	1.2490009027033E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1.86

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	13.02	-	11.159
	=	1.86

InMed Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.407	+	(0.667	+	-2.2204460492503E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2.07

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	12.29	-	10.217
	=	2.07

InMed Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals (FRA:MWG0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

INM:USA MWG0:Germany

Address

815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines